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Human immunodeficiency virus (HIV) infection is associated with haematological 
changes, including thrombocytopaenia. Pregnancy induces a hypercoagulable 
state. There are limited data on the coagulation status of women with term 
pregnancy and HIV receiving anti-retroviral medication. Regional anaesthesia is the 
technique of choice for caesarean section, and is contraindicated in a hypo-
coagulable state. We therefore investigated the coagulation status of term pregnant 
women with HIV, presenting for elective caesarean section (CS). This was a single-
centre cross-sectional observational study, using thromboelastography, comparing 
the coagulation status of HIV negative and -positive women with no other 
comorbidities, in pregnancy at term. A blood sample was taken immediately prior to 
spinal anaesthesia, and thromboelastography was performed within 4 minutes. In 
addition, platelet count, haemoglobin, and fibrinogen level were measured. Blood 
samples were obtained from 75 patients. There were no between-group differences 
in obstetric and demographic data, and no difference in platelet count. The mean 
(SD) fibrinogen level was higher in HIV positive women (3.9 [1.5] vs 3.5 [0.7] g/L) 
respectively, p=0.04. There were no significant differences in the r-time, alpha-
angle, k-time, MA, or LY-30. The results of this thromboelastography study show 
that in asymptomatic HIV positive pregnant patients on anti-retroviral treatment, 
there are no significant differences in coagulation parameters when compared with 
HIV negative patients. This suggests that routine assessment of coagulation is 
unnecessary before spinal anaesthesia in patients without other co-morbidities. 
Further studies could demonstrate the incidence of abnormalities in coagulation or 
platelet function in patients with AIDS defining disease or HIV positive patients with 









Coagulation in the HIV positive pregnant patient: a thromboelastography study 
Introduction 
In 2017, South Africa was estimated to have a prevalence of human 
immunodeficiency virus (HIV) infection in adults aged 15-49 years, of 18.8% [1]. The 
2015 National Antenatal Sentinel HIV and Syphilis Survey in South Africa estimated 
a prevalence of 30.8% amongst women presenting for antenatal care, the lowest 
being in the Western Cape Province (18.9%) [2]. 
HIV infection is known to be associated with haematological changes. The most 
common is anaemia, found in 95% of patients in the course of their disease. 
Thrombocytopaenia is also a feature, the most common cause of which is immune 
thrombocytopaenia [3]. The changes in the coagulation system could collectively 
represent a hypocoagulable state. Pregnancy is well known to induce a 
hypercoagulable state; other haematological features include a dilutional anaemia 
and relative thrombocytopaenia [4]. 
Regional anaesthesia is the technique of choice for CS in the parturient in the 
absence of contraindications, and has been shown to decrease morbidity and 
mortality in HIV positive patients undergoing elective CS [5,6]. 
Thromboelastography (TEG) has been extensively utilised in previous studies to 
demonstrate the coagulation status of pregnant patients [7,8], and the measured 
parameters influence the decision to perform regional or general anaesthesia for 
CS. 
There are limited studies examining the effect of HIV infection and anti-retroviral 
medication on coagulation in pregnancy [6,9]. We therefore performed a cross-
sectional study comparing the coagulation profile (as assessed by TEG) of HIV 
positive versus -negative patients at term. Secondary outcomes included a 
comparison of TEG variables in patients in whom anti-retroviral therapy (ART) had 
been commenced before or during pregnancy. In addition, between-group 







This was a single centre observational study, which was approved by the Human 
Research Ethics Committee of the Faculty of Health Sciences of the University of 
Cape Town (HREC Ref: 241/2013). Patients were recruited prior to elective CS at 
Mowbray Maternity Hospital, Cape Town, South Africa, from August 2013 to April 
2014. Informed consent was obtained from all patients by the principal investigator 
at least 12 hours prior to CS. The standard of care at this hospital is for all patients 
to be screened for HIV infection as part of the antenatal assessment. All blood 
specimens drawn during the study were labelled with study- specific labels, 
rendering patients anonymous. The results of the study had no effect on the quality 
of care received by the participants. 
Immediately prior to spinal anaesthesia, a 16- or 18-gauge intravenous cannula was 
inserted. A blood sample of 10 mL was taken from the cannula. The initial 8 mL was 
placed in an EDTA tube (BD Vacutainer ® K3E 7.2 mg) for measurement of platelet 
count; haemoglobin (Hb) level and CD4 count, if the latter had not been performed 
within six months of participation in the study. The remaining 2 mL of the specimen 
was placed in a citrated tube (VACUETTE ® 9NC Coagulation Sodium Citrate 
3.2%) for the assessment of the fibrinogen level. A separate syringe was used to 
withdraw a further 2 mL of blood for TEG measurements after the initial sampling, 
thus eliminating contamination by tissue factors that could affect the results. An 
aseptic venipuncture was performed if there was difficulty in obtaining a satisfactory 
blood sample from the cannula. 
All TEGs were performed on site within four minutes of sampling by a qualified 
technologist using the TEG ®5000 Haemostasis Analyzer System (Haemonetics ® 
Corp, Braintree, MA, USA; Software version 4.2). Regular quality control and 
calibrations were performed according to manufacturer’s recommendations. One 
mL of native blood was activated using kaolin, and 360 µL pipetted into a cup that 
had been pre-warmed to 37 degrees Celsius. The same technologist performed all 
the TEGs, thus eliminating inter-individual variability in performing the test. The 
samples ran for a period of 60 minutes. The mean (SD) r time (time taken for clot 
formation to start), k time (time from end of r time until the clot reaches 20 mm), α 
angle (the tangent of the curve when the k time is reached), maximum amplitude 




strength, and LY30 (percentage decrease in MA after 30 minutes) [10] were 
recorded and compared between HIV-positive and -negative patients.  
The platelet count, Hb level, CD4 count and fibrinogen levels were all performed by 
the National Health Laboratory Service (NHLS) at Groote Schuur Hospital. 
Reference ranges were applied as per NHLS standards. Estimated blood loss was 
recorded by the attending senior anaesthetist, using observation of swabs, 
measurement in suction bottles, and assessment of surgical field losses. 
Demographic data is presented as mean ± SD. TEG data was analysed using the 
paired t test and Wilcoxon signed rank test. The required sample size was 
estimated for this comparison of TEG parameters between HIV-positive and-
negative women, using similar methodology to that of Butwick et al [11]. A 20% 
difference in TEG ® parameters was regarded as a clinically relevant endpoint for 
the study. Assuming an r-time estimate for the normal pregnant population of 6.5 
minutes, with a standard deviation (SD) of 2.5 minutes, 32 patients would be 
required in each group to detect a 1.5 minute difference in the HIV-positive group 
greater or less than the r-time in the control group, with 80% power and alpha error 
0.05. Seventy five patients were recruited, to account for possible errors in the 
processing of samples. The statistical programme used was Statistica Version 11 
(StatSoft Inc, Tulsa, USA).  
Results 
Blood samples were obtained from 75 patients, of whom 38 were HIV-positive and 
37 HIV-negative. Obstetric and demographic data is presented in Table 1.  
There were no significant between-group differences. Laboratory data are 
presented in Table 2. Four specimens were discarded by the laboratory due to 
inadequate volume for analysis. The fibrinogen level in the HIV positive patients was 
higher than in the control group (p=0.04). The TEG values for the two groups are 
presented in Table III. There was no significant difference in the r-time, alpha-angle, 
k-time, MA, or LY-30. The results were not influenced by the timing of 








This cross-sectional comparison of TEG parameters in pregnant women close to 
term, showed no significant differences between HIV-positive and -negative 
patients, except for a clinically insignificantly higher fibrinogen level in HIV positive 
women. Clot strength as evidenced by the MA was also not significantly different. 
The LY-30 in both groups showed no evidence of fibrinolysis. As all of the patients 
in the HIV cohort were on ART during the time of this study, no conclusions can be 
drawn as to the effect of ART on coagulation parameters. There were also no 
between-group differences in platelet count, fibrinogen level, or blood loss at 
caesarean delivery.  
Regional anaesthesia is the preferred method in pregnancy, where epidural 
anaesthesia is the gold standard for labour analgesia, and spinal anaesthesia 
predominates for CS, avoiding the risks of general anaesthesia, such as failed 
tracheal intubation. The presence of coagulation abnormalities influences the 
decision to perform regional anaesthesia in pregnancy. The high prevalence of HIV 
infection in the South African population and the increasing rate of CS necessitates 
the understanding of haematological changes and the implications for regional 
anaesthesia. 
HIV causes endothelial dysfunction with activation of the coagulation system. This is 
evidenced by the finding of elevated D-dimer- and thrombin-anti thrombin complex 
levels [9,12], a progressive increase of Factor VIII levels, and a decline in functional 
Protein S and Protein C levels. These changes are more pronounced with 
advancing disease [3,13]. The presence of lupus anticoagulant and antiphospholipid 
antibodies, which are associated with a prothrombotic state, may also contribute to 
HIV infection- associated thrombosis [3,13], although this is controversial [13,14]. 
Pregnancy is associated with an increase in pro-coagulant factors (II, VII, VIII, X and 
XI) and a decrease in anti-coagulant factors (Protein C and S, and Antithrombin III) 
[4,9]. Fibrinogen levels rise from 28 weeks’ gestation, and D-dimer levels are raised 
throughout pregnancy. These haematological occurrences are thought to be a 
physiological adaptation to minimise blood loss during childbirth [4]. Karlsson et al 
showed increased coagulation in Scandinavian women [15], as did Gorton et al in 




The maximal amplitude (MA) on the TEG tracing is a measure of clot strength, and 
is a direct indication of fibrinogen and platelet interaction [17]. The MA has therefore 
been found to correlate well with platelet count [18]. The increased fibrinogen level 
in pregnancy may reduce the effect of thrombocytopaenia on the TEG tracing, as 
both contribute to the MA [19]. Thrombocytopaenia is one of the earliest 
manifestations of HIV infection [20] and immune thrombocytopaenia is the most 
common cause [3].  Two previous studies in healthy patients found MA (mean) 
values of 66.4 [7] and 75.4 [21]. The latter study found fibrinogen levels of 5.0 g/L 
(3.7-6.4). These values are similar to those found in our study (MA 74.1 in the HIV 
negative- and 72.7 in HIV positive patients), although fibrinogen levels in our 
population were lower. These results indicate that asymptomatic HIV positive 
parturients remain within normal limits for this parameter, as suggested by previous 
studies. The findings in one study in HIV positive patients in the non-obstetric 
population, have suggested defects in platelet function. There was reduced 
aggregation in response to thrombin receptor-activating peptide (TRAP), adenosine 
phosphate (ADP) and collagen. In addition, an increased response to epinephrine 
(EPI) was shown using a platelet aggregation assay, when comparing HIV positive-, 
80% of whom were on ART, and -negative patients [22]. 
A study by Arildsen et al, which compared haematological changes in HIV positive 
patients before and after highly active anti-retroviral therapy (HAART), found 
endothelial dysfunction, lower fibrinogen levels and higher D-dimer levels prior to 
treatment. The raised D-dimers did not fully correct following a treatment period of 
six months [12].  Haugaard et al also found increased D-dimer levels in untreated 
HIV positive patients, but still found that these patients were relatively 
hypercoagulable as assessed by TEG [23].  
A further study found that HIV patients on ART had increased levels of tissue 
plasminogen activator antigen (t-PA) and plasminogen activator inhibitor type 1 
(PAI-1), which suggests increased fibrinolysis [9]. Our study found no between-
group difference in fibrinolysis as assessed by the LY30, which may related to the 
fact that our patients were receiving ARV therapy [12]. 
The findings of our study, comparing the coagulation status using TEG of HIV 
positive and -negative patients, suggests that in asymptomatic HIV positive patients, 
routine laboratory or point of care coagulation studies are not indicated before 




thrombocytopaenia in asymptomatic patients scheduled for caesarean delivery, 
which found that only preeclampsia was predictive of mild thrombocytopaenia. A 
sub-analysis in that study showed that HIV status was not independently associated 
with moderate thrombocytopaenia, and that all asymptomatic patients had a platelet 
count >70 000/µL. The authors concluded that on this basis a routine full blood 
count is indicated in preeclampsia, but not in patients who are HIV positive, unless 
there are other comorbidities [24]. 
Davies et al evaluated differences in healthy pregnant- versus preeclamptic women 
using the Platelet Function Analyzer (PFA-100) and TEG. This study found a mean 
MA of 73 mm, and that despite an abnormal clotting time in the preeclampsia 
cohort, the MA remained within the normal range. This indicates that TEG may not 
detect abnormalities in primary haemostatic function [19]. 
A limitation of our study was that we did not study platelet function, or the effect of 
ART, since most of our patients were receiving this medication at the time of the 
study. 
In conclusion, the results of this thromboelastography study show that in 
asymptomatic HIV positive pregnant patients on ARV treatment, there are no 
significant differences in coagulation parameters when compared with HIV negative 
patients. This suggests that routine assessment of coagulation is unnecessary 
before spinal anaesthesia in patients without further co-morbidities. Further studies 
could demonstrate the incidence of abnormalities in coagulation or platelet function 
in patients with AIDS defining disease or HIV positive patients with other co-
morbidities.  
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Table 1. Obstetric and demographic data presented as mean (standard deviation) 
 HIV positive (n=38) HIV negative (n=37) 
Age (years) 32.18 (4.61) 30.40 (5.17) 
Weight (kg) 88.03 (14.17) 88.19 (16.87) 
Gestational age (weeks) 38.92 (0.88) 39.27 (0.87) 
CD4 count (cells/µL) 546 (239) N/A 
Estimated blood loss (mL) 516 (255) 469 (280) 
HIV: human immunodeficiency virus 
Table 2. Laboratory data 
 HIV positive HIV negative p-value 
Haemoglobin (g/dL) 11.7 (1.3) 11.8 (1.4) 0.62 
Platelet count (x109/L) 246.8 (59.0) 261.7 (64.4) 0.29 
Fibrinogen (g/L) 3.9 (1.5) 3.5 (0.7) 0.04 
 
Table 3. The TEG values for both groups  
 HIV positive HIV negative p-value 
r time (minutes) 4.83 (1.66) 4.21 (1.51) 0.09 
k time (minutes) 1.50 (0.39) 1.41 (0.65) 0.49 
α angle (degrees) 67.66 (1.66) 69.47 (6.96) 0.23 
maximum amplitude (mm) 72.69 (3.78) 74.10 (6.57) 0.25 
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appropriate. Results (including actual p values) must be presented for all measurements 
detailed in the Methods section, and in the same order. Results should not be repeated 
unnecessarily. For example, if a graph is used, do not also present the same 
information in the text or in a Table. Results should not be given to an unwarranted 
number of decimal places and 95% confidence intervals should be used where possible 
(see Statistics, below). 
In randomised trials, baseline data (age, ASA physical status, duration of operation, 
etc.) should not be subjected to statistical comparison, since it is already known that the 
subjects were randomly allocated and that any difference is therefore due to chance. 





When reporting the effect of an intervention, absolute risk (AR), relative risk (RR) and 
‘number needed to treat’ (NNT) are more easily understood by readers and may be 
preferable to odds ratio (OR). 
Graphs and Tables should be appropriate for the data to be displayed. Tables usually 
convey more precise numerical information; graphs should be reserved for highlighting 
changes over time or between treatments. 
Report actual p values, rather than ranges or limits (e.g. p = 0.032, rather than p < 
0.05). 
• Use ‘survival’ curves for outcomes that are time, e.g. ‘time to extubation‘ or ‘time 
to hospital discharge’, particularly if it is the primary outcome 
• Means should be expressed to a sufficient precision that they are different, with 
a minimum of three significant digits e.g. 372, 37.2, 3.72, 0.372 etc. 
• Means should be followed by the standard deviation, not the standard error. 
• Standard deviations do not need to be different and should be a minimum of two 
significant digits. 
• Rates should be followed by proportion if the denominator exceeds 100, e.g. 
90/200 (45%) but 9/20. 
Discussion 
The Discussion should present an interpretation of the results against a background of 
existing knowledge. Any conclusions must be warranted by the results. Avoid a 
paragraph headed ‘Conclusions’ that merely repeats a summary of the results. 
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Information or data not directly a result of the study but necessary for the reader to 
understand the manuscript should be included as an Appendix. Examples might include 
copies of questionnaires, recognised mathematical processes used to generate results 
or previously published and validated classification systems. All should be appropriately 
referenced and authors must obtain permission from the copyright holders if the 
contents have been previously published. 
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References must be numbered sequentially as they appear in the text. References cited 
in Figures or Tables (or in their legends and footnotes) should be numbered according 
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reviewed journals. Internet sites may be quoted as references by listing them in the 
normal way in the text. Unpublished observations, personal communications and 




the manuscript in parentheses. Information from manuscripts submitted but not yet 
accepted should be cited in the text as unpublished observations. References cited for 
the first time in Tables or Figures should be numbered in the sequence established by 
the first mention of the particular Table/Figure in the text. All references (including those 
in press) should be listed at the end of the text in the order they are quoted. For internet 
sites, please include the date accessed in parentheses. List all authors unless there are 
seven or more, in which case give the first three followed by ‘, et al.’ Journal titles should 
be written in full and in italics, followed by a semi-colon then a space followed by the 
volume number in bold (issue numbers are not required) then a colon then a space and 
finally the page numbers. The Anaesthesia Endnote template may be found here. 
Examples: 
1. Author AB, Author CD. Title of paper. Journal Title Written Out in Full in 
Italics 2019; 12: 123-4. 
2. Author AB, Author CD. Title of paper published as 'ePub ahead of print'. Journal 
Title Written Out in Full in Italics 2019. Epub ahead of print 15 Dec; doi 
xx.xxxx/xxx.xxxxxx. 
3. Author AB, Author CD, Author EF, et al. Seven or more authors – what’s the 
point? (chapter title). In: Editor GH, Editor IJ, eds. Title of Book. Place: 
Publisher, 2019: 345-67. 
4. Author AB. Book Title, 5th edn. Place: Publisher, 2019. 
5. Author(s) of website. Title of document/page, 
2019. www.URL.co.uk/link.pdf (accessed 01/01/2019). 
The International Committee of Medical Journal Editors has stated that: "Authors 
are responsible for checking that none of the references cite retracted articles except in 
the context of referring to the retraction. For articles published in journals indexed in 
MEDLINE, the ICMJE considers PubMed the authoritative source for information about 
retractions. "Retracted articles can be identified by using the following search strategy in 
PubMed, e.g. for an author J. Smith enter "Smith*J AND retracted publication[pt]". 
Tables 
Include Tables in the same file as the text, but after the References. Each Table should 
be on a separate page. Number the Tables consecutively with Arabic numerals. Each 
Table should have a brief caption immediately above it; this should provide enough 
information for readers to follow the Table without having to look through the text (e.g. 
‘Characteristics of patients receiving vecuronium or rocuronium for caesarean section’ 
rather than just ‘Patients’ characteristics’). The caption should explain whether the 
values refer to mean (SD), number (proportion), etc. Abbreviations should not be 
mentioned in the caption without explanation. Abbreviations used in the body of the 
Table should be explained as footnotes in the order in which they are first mentioned. 
For adults: age, weight, height and BMI should be expressed as mean (SD). For 
children: age, weight, height and BMI should be expressed as median (IQR [range]). 
Study groups should form the columns rather than the rows. If statistical comparisons 
are being made, a separate column with exact p values should appear. 
Figures 
Please supply each Figure as a separate file and not embedded within the Word 
document. We ask that Figures are supplied at a resolution of 300 pixels per inch for 
photographs and 600 pixels per inch for line art or a combination of photograph and 
labelling. Please do not send image files larger than 10MB. Further guidance can be 
found here. 
Please ensure related graphs have the same format (fonts, use of symbols, etc.), and 
that the groups are presented in the same order in each graph (and in the same order 
as in the rest of the manuscript). The same requirements for abbreviations and units 




gridlines or legend boxes within the graphs, and symbols and error bars should be 
explained in the caption. Avoid the use of 3-D unless absolutely necessary. Colour 
figures (e.g. photographs, complex flow diagrams, etc.) may be used without charge. 
Captions for Figures 
Each Figure caption should include an explanation of the symbols used to provide 
enough information for readers to follow it without having to look through the text. 
Supporting Information (online only) 
Additional material such as video clips, lengthy Appendices (e.g. extensive reference 
lists or mathematical formulae/calculations), etc. which are relevant to a particular article 
but not suitable or essential for the print edition of the Journal, may also be considered 
for publication. Please refer to all supporting information in the manuscript using Table 
S1, Figure S1, etc. and supply as separate files. Further information on suitable file 
formats may be found here. 
Language 
Anaesthesia uses UK English spelling e.g. “ise” not “ize”, “anaesthesia” not 
“anesthesia”, etc. Please avoid long, complicated sentences and the passive voice 
when the active is more appropriate (e.g. ‘We chose epidural anaesthesia because...’ 
instead of ‘Epidural anaesthesia was chosen by the authors because...’). Focus on the 
actual message of each sentence; thus ‘Hypotension is important because...’ instead of 
‘It would be remiss of us not to mention hypotension because...’. Remember that lungs 
are ventilated, not patients (nor are they intubated – their tracheas are). 
Similarly, patients are not induced – anaesthesia is – or put on ventilators. Correct terms 
are tracheal (not endotracheal) tube and neuromuscular blocking drugs (not muscle 
relaxants). Please refer to recent issues of the Journal for preferred wording/spelling. 
The abbreviation LMA is only to be used if referring to a specific device made by The 
Laryngeal Mask Company Ltd, and with the first mention in the Summary and in the 
main text highlighted by (R) and ‘LMA is a registered trademark of The Laryngeal Mask 
Company Ltd, an affiliate of Teleflex Incorporated’ as a footnote. If used, the correct 
format is ‘LMA® laryngeal mask’ for the first mention (n.b. not just ‘LMA®’) and ‘LMA 
laryngeal mask’ thereafter. The same to apply to LMA® Classic, LMA® Flexible, LMA® 
Fastrach (n.b. previously labelled ILMA®), LMA® ProSeal, LMA® Supreme, LMA® 
Unique (n.b. ‘cLMA’ not to be used). The generic term of ‘laryngeal mask’ should be 
used for describing inflatable-cuff supraglottic airways in general. 
Abbreviations 
The Journal does not encourage the use of abbreviations, especially in the Summary, 
since their frequent use makes papers difficult to read. We will accept abbreviations in 
the following circumstances: 
• Universal abbreviations that do not need to be written out in full when first 
mentioned in the text, e.g. ASA, BMI, ECG, ICU, HDU, SD, SEM, 95% CI, IQR, 
ANOVA, SpO2, FIO2, pH. 
• Acceptable common abbreviations should be written out in full at their first 
mention, e.g. CNS, CSF, HME, PEEP, PCA, SCBU, CTG, EEG, BIS, CVP, 
PAP, PCWP, ECT – unless they are only mentioned a few times, in which case 
please spell them out throughout. Please do not use abbreviations that are 
clumsy or will be unfamiliar to the majority of readers, e.g. DI (difficult 
intubation), TTFB (time to first breath), etc. 
• Acceptable abbreviations whose use should be restricted to situations where 
space is limited, such as in formulae or in Tables and Figures, e.g. O2, CO2, N2O, 
HCO3-, Na+, K+, Mg2+. 
Numbers and units 
Numbers should be spelled out in full when they start a sentence, and when they are 




later, five patients each received 7 ml solution...’ Commas are used to indicate 
thousands above 10,000: thus, 2000 and 20,000. Please give costs in sterling (£) with 
equivalent Euros and US dollars (€/$) in brackets. 
 
Use the format mg.kg-1 not mg/kg for all units. Use SI units throughout the text except for 
vascular pressure measurements (mmHg or cmH 2O) and haemoglobin concentration 
(g.l-1). Litres are indicated by lower case ‘l’. Use the 24-hour clock for times. 
Ethical considerations 
Manuscripts will only be considered for publication in Anaesthesia if they adhere to the 
highest ethical standards. These are detailed in two editorials published in the journal, 
that are available here and here and which potential authors are strongly advised to 
consult. 
The Editorial Board takes all cases of possible publication misconduct seriously and will 
investigate these according to the recommendations of the Committee on Publication 
Ethics (COPE). Further guidance can be found in our Editorial Policies. 
 
All clinical trials that prospectively assign human subjects to intervention or comparison 
groups to study the cause-and-effect relationship between a medical intervention and a 
health outcome should be registered before the time of first recruitment. There are 
several public registries now available which meet the requirements of the ICMJE and 
these are listed on the WHO International Clinical Trials Registry Platform. The 
registry, registration number and date of registration must be stated in the 
Acknowledgements section of the manuscript. This should have been done before 
patient recruitment commenced. Reports of original research that were not registered 
before the study was carried out should include separate submission of the original 
protocol for the study. If the submitted report differs from the protocol, an explanation of 
the reason for this should be provided. Authors should be willing and able to submit their 
raw study data to the journal, if requested, after submission. 
Anaesthesia supports and encourages the use of the EQUATOR (Enhancing the 
QUAlity and Transparency Of health Research) Network guidelines to ensure the 
transparent and accurate reporting of research studies. The authors of clinical 
intervention studies are advised to review the CONSORT statement regarding the 
reporting of randomised trials prior to manuscript submission. 
We strongly encourage authors to register systematic review protocols on a similar 
database (for instance, PROSPERO http://www.crd.york.ac.uk/PROSPERO/). 
All clinical trails should be conducted in accordance with the ethical principles as set out 
in the Declaration of Helsinki. In brief, the minimum ethical standards 
for Anaesthesia include: 
• Approval by a Research Ethics Committee (REC) or equivalent Institutional 
Review Board (IRB) must be obtained prospectively for all studies on human 
subjects, including studies in which participants’ skills are tested using manikins. 
Some studies involving audit and epidemiological surveys, assessments of 
medical equipment or analysis of previously collected, non-identifiable 
information from a database may be exempt from this stricture if participants are 
appropriately protected against coercion and there is due regard to 
confidentiality. Publication of the results, however, would usually still require 
informed consent and assurances regarding confidentiality (including approval 
by  the Caldicott Guardian or equivalent for patient data and the relevant 
Research and Development department), even if the REC/IRB has indicated 
that formal submission is unnecessary. 
• While an essential preliminary step, REC/IRB approval does not guarantee the 
ethical standards of a study will meet the requirements of the Editorial Board of 




publication, they are invited to contact the Editor-in-Chief before embarking on 
the study. 
• The Editorial Board supports the view of the ICH Harmonised Tripartite 
Guideline for Good Clinical Practice that full prospective written informed 
consent should be obtained from all subjects of clinical trials, including 
participants in manikin studies (see above). This would normally comprise 
provision of written information to potential research participants, allowance of 
adequate time for them to consider their involvement and ask questions, and the 
use of specific consent forms (for the study, not just for routine 
surgery/anaesthesia) that should be signed by the participants to indicate their 
consent and stored in case they require examination later. 
• Studies of novel treatments, in particular drug studies where the agent used is 
given via unlicensed routes (especially neuraxial or perineural), may have 
received approval from the REC/IRB, but the Editorial Board is likely to reject 
such studies if it considers the risks posed outweigh the potential benefits. Such 
a conclusion is more likely to be reached if the drug in question is not widely 
used in routine practice (as evidenced by inclusion in standard textbooks), if the 
study participants are especially vulnerable (e.g. children, women in labour), if 
there are questions over consent, or if only modest improvements in outcome 
are expected where other, well established methods already exist. 
• Animal studies will only be considered for publication if they have ethical and 
governmental approval, and have been conducted under appropriate standards 
of care. Researchers will be expected to follow the ARRIVE guidelines for 
experimentation in animal research.  
Statistics 
The following guidelines may help authors present their work in a better and more 
rigorous way that avoids common statistical errors that frequently lead to rejection. This 
is not an exhaustive list and, of course, the Editorial Board and reviewers of manuscripts 
may ask authors for revisions that are not detailed here. Authors are advised that it is a 
condition of submission that they be prepared to send individual patient data, or other 
data, to be checked. 
Methods 
Randomisation methods should be made explicit (e.g. coin toss, random numbers, etc.). 
Please describe if stratification of the allocation system in a randomised controlled trial 
is performed (e.g. by age or recruiting centre) or block (permuted sequence or 
otherwise). For instance, most anaesthetic randomised controlled trials have exactly the 
same number of patients in each group but do not mention any blocking method (which 
would include putting equal numbers of folded pieces of paper for each group in an urn). 
Blinding must be as good as possible within constraints of clinical practice. 
Where there are several outcomes to be reported, the most important (primary) 
outcome should be clearly stated, along with any secondary outcomes. Beware of 
reporting as ‘significant’ or ‘important’ a positive result of a secondary outcome, when 
the study was in fact powered (sample sized) to a different primary outcome. 
Power analysis 
Some justification of sample size is always necessary for all observational studies, 
randomised or non-randomised controlled trials, or other types of study. Justification 
may be quantitative or qualitative (e.g. a ‘convenience sample’), although the latter may 
be regarded as weaker than the former. Details provided (for continuous variables) 
should include the power level; the significance level at which a result is sought; and the 
expected control and study group proportions or mean and pooled SD, in order to allow 
reviewers and readers to follow the calculation. The method used to justify power should 
be referenced and enough detail provided, so that the calculation can be repeated by 
readers. Conventionally, the power of study should be at least 80% but where different 




designed to detect should indeed be clinically relevant. Beware of setting an 
unreasonably large ‘clinically important difference’ to justify small sample size, as 
reviewers will recognise this is done simply to facilitate a small study. 
General rules: 
• Use mean (SD) unless data are discrete (e.g. Apgar scores, sedation scores) or 
grossly non-normally distributed: use median (IQR [range]) or you are interested 
in the ‘true’ value for the population (use SEM). 
• Visual analogue scores (VAS) for pain may be treated as continuous data and 
be subjected to parametric tests as long as the sample size is large (> 50) and 
the data appear normally distributed. VAS for other modalities (nausea, 
drowsiness) have not been so extensively validated and are best treated as 
ordinal data. 
• Scales of measurement can be problematic (e.g. Cormack-Lehane scale, VAS, 
etc.) because a value of say 2 on the scale does not imply something twice the 
value of 1, etc. So they cannot logically be regarded as linear, continuous 
scales. It is safer to regard them as ordinal scales. However, for some scales 
such as VAS for pain it appears established norm that this may be regarded as 
continuous, especially for large sample sizes (e.g. >50). 
Inferential statistics 
• Use simple statistical tests where possible. 
• Avoid multiple comparisons, or correct for them if used. 
• Reference unusual tests; and assume that the more unusual the test, the more 
likely it is that a specialist statistical referee will review the paper. 
• Include details of any computer package/version used. 
•   
• When looking for relationship between variables, use correlation to describe a 
simple descriptive association between two variables. 
• Use regression to describe a quantitative relationship between two or more 
variables, especially where one is predictive and other(s) dependent. Non-linear 
regression may be appropriate. Regression methods yield a formula to relate 
the variables being described. 
• Use the Bland-Altman method to describe the performance of two different 
methods used in measurement, analysis or diagnosis. 
Conclusions 
All conclusions should be warranted by the results and not extend beyond the confines 
of the study conditions. A negative result does not mean that there is definitely no 
difference (confidence in the conclusion is dependent upon the power of the study), and 
a positive result does not mean that there definitely is a difference (confidence in the 
conclusion is dependent upon the alpha error). The journal has a very useful statistics 
section containing articles which authors may find useful in preparing their manuscripts 
for statistical content. 
